Investigational Drug Information for BTZ-043
✉ Email this page to a colleague
What is the drug development status for BTZ-043?
BTZ-043 is an investigational drug.
There have been 5 clinical trials for BTZ-043.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 9th 2024.
The most common disease conditions in clinical trials are Tuberculosis, Pulmonary, Tuberculosis, and Bacterial Infections. The leading clinical trial sponsors are Michael Hoelscher, German Center for Infection Research, and German Federal Ministry of Education and Research.
There are five US patents protecting this investigational drug and forty-six international patents.
Summary for BTZ-043
| US Patents | 5 |
| International Patents | 46 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 1 (2024-01-09) |
| Vendors | 47 |
Recent Clinical Trials for BTZ-043
| Title | Sponsor | Phase |
|---|---|---|
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB | Critical Path Institute | Phase 2 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB | European Lung Foundation | Phase 2 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB | European Respiratory Society | Phase 2 |
Clinical Trial Summary for BTZ-043
Top disease conditions for BTZ-043
Top clinical trial sponsors for BTZ-043
US Patents for BTZ-043
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| BTZ-043 | ⤷ Sign Up | Compositions and methods for inhibiting bacterial growth | Board of Trustees of Michigan State University (East Lansing, MI) | ⤷ Sign Up |
| BTZ-043 | ⤷ Sign Up | Indole carboxamide derivatives and uses thereof | Novartis AG (Basel, CH) | ⤷ Sign Up |
| BTZ-043 | ⤷ Sign Up | Pyridone derivatives and uses thereof in the treatment of tuberculosis | Novartis AG (Basel, CH) | ⤷ Sign Up |
| BTZ-043 | ⤷ Sign Up | Combination therapy to treat Mycobacterium diseases | SPERO TRINEM, INC. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for BTZ-043
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| BTZ-043 | Taiwan | TW201708818 | 2035-08-11 | ⤷ Sign Up |
| BTZ-043 | World Intellectual Property Organization (WIPO) | WO2017027062 | 2035-08-11 | ⤷ Sign Up |
| BTZ-043 | World Intellectual Property Organization (WIPO) | WO2016179231 | 2035-05-04 | ⤷ Sign Up |
| BTZ-043 | Australia | AU2013311235 | 2032-09-07 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
